GeoVax Labs (GOVX) Competitors

GeoVax Labs (NASDAQ:GOVX) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Does the media favor GOVX or IPSC?

In the previous week, Century Therapeutics had 3 more articles in the media than GeoVax Labs. MarketBeat recorded 5 mentions for Century Therapeutics and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.45 beat Century Therapeutics' score of -0.22 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
Century Therapeutics	Neutral

Do analysts recommend GOVX or IPSC?

GeoVax Labs presently has a consensus target price of $8.50, suggesting a potential upside of 1,111.00%. Century Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 648.80%. Given GeoVax Labs' higher possible upside, research analysts clearly believe GeoVax Labs is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, GOVX or IPSC?

GeoVax Labs has a beta of 3.57, meaning that its stock price is 257% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Is GOVX or IPSC more profitable?

Century Therapeutics has a net margin of -19.10% compared to GeoVax Labs' net margin of -403.88%. Century Therapeutics' return on equity of -11.53% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	-403.88%	-408.80%	-279.89%
Century Therapeutics	-19.10%	-11.53%	-6.94%

Which has higher valuation & earnings, GOVX or IPSC?

GeoVax Labs has higher earnings, but lower revenue than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$3.95M	2.83	-$24.99M	-$2.01	-0.35
Century Therapeutics	$6.59M	6.57	-$126.57M	-$0.29	-1.73

Do insiders and institutionals have more ownership in GOVX or IPSC?

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 1.2% of GeoVax Labs shares are held by company insiders. Comparatively, 5.0% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Century Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.